The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shmelev E.I.

Otdel pul'monologii Tsentral'nogo NII tuberkuleza RAMN, Moskva

Idiopathic pulmonary fibrosis: The current state of the problem

Authors:

Shmelev E.I.

More about the authors

Journal: Therapeutic Archive. 2016;88(12): 103‑108

DOI: 10.17116/terarkh20168812103-108

Read: 21667 times

Download PDF (RU)
Contact the author
Table of contents

IDIOPATHIC PULMONARY FIBROSIS: THE CURRENT STATE OF THE PROBLEM
IDIOPATHIC PULMONARY FIBROSIS: THE CURRENT STATE OF THE PROBLEM

To cite this article:

Shmelev EI. Idiopathic pulmonary fibrosis: The current state of the problem. Therapeutic Archive. 2016;88(12):103‑108. (In Russ.)
https://doi.org/10.17116/terarkh20168812103-108

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59
Inte­rventricular septum anatomy in obstructive hype­rtrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):15-22
Resu­lts of the All-Russian consensus conference on complications in bariatric surgery. Endo­scopic Surgery. 2025;(1):15-24
X-ray endo­scopic classification of aspi­ration syndrome. Endo­scopic Surgery. 2025;(1):31-37
Infe­ctious factors in atopic dermatitis, pharmaceutical possibilities (systematic lite­rature review). Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):7-15
A modern perspective on the pathogenesis of proliferative diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(1):92-98
On the issue of classification of vomer defo­rmities in children. Russian Bulletin of Otorhinolaryngology. 2025;(1):35-42
Possibilities of computed tomo­graphy of lungs in diagnosis and differential diagnosis of hype­rsensitive pneumonitis (literature review). Journal of Respiratory Medi­cine. 2025;(1):23-29
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Abstract:

Idiopathic pulmonary fibrosis (IPF) is a severe lung disease, with death occurring within 2-5 years after its onset. IPF affects people in the second half of life. Its causes are unknown. Before 1999, IPF was out from the group of idiopathic interstitial lung diseases as a separate nosological entity. Practitioners very often (80%) make diagnostic errors in IPF and prescribe antibiotics, anti-inflammatory drugs, which worsen the course of this disease. The distinctive feature of the pathogenesis of IPF is the absence of inflammation, which is clinically manifested by the inefficacy of glucocorticosteroids and other anti-inflammatory drugs. Pharmacological agents for the treatment of IPF have been designed since 2000. One of them has been registered and permitted for use in the Russian Federation. This paper is a review of an update on the problem of IPF, which should facilitate the appropriate orientation of physicians in diagnosing and treating this severe disease.

Keywords:

interstitial lung diseases
idiopathic interstitial pneumonias
idiopathic pulmonary fibrosis
classification
pathogenesis
treatment

Authors:

Shmelev E.I.

Otdel pul'monologii Tsentral'nogo NII tuberkuleza RAMN, Moskva

Close metadata

References:

  1. American Thoracic Society/European Respiratory Society Classification of the Idiopatic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277-304. doi:10.1164/ajrccm.165.2.ats01
  2. Raghu G, Wwycker D, Edelberg J et al. Incidence and prevalence of Idiopathic Pulmonory Fibrosis. Am J Respir Crit Care Med. 2006;174:810-816. doi:10.1164/rccm.200602-163OC
  3. Idiopathic Pulmonory Fibrosis: Diagnocis and Treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161:646-664. doi:10.1164/ajrccm.161.2.ats3-00
  4. Raghu G, Collard HR, Egan JJ et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. doi:10.1164/rccm.2009-040GL
  5. Luppi F, Spagnolo P, Cerri S, Richeldi L. The big clinical trials in Idiopathic Pulmonory Fibrosis. Curr Opin Pulm Med. 2012;18;428-432. doi:10.1097/MCP.0b013e3283567ff9
  6. Raghu G, Anstrom KJ, King TE et al. Idiopathic Pulmonory Fibrosis Clinical Research Network. Prednisolone, azatioprine- and N-acetylcystein for pulmonary fibrosis. N Engl J. 2012;366;1968-1977. doi:10.1056/NEJMoa1113354
  7. Raghu G, Bram R, Yuan Z et al. An OfficialATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonory Fibrosis: Executive Summary/Update of the. 2011 Clinical Practice Guideline Am J Respir Crit Care Med. 2015;192(2):237-248. doi:10.1164/rccm.201506-1063ST
  8. Il'kovich MM. Interstitsial'nye zabolevaniya legkikh: rassuzhdeniya na aktual'nuyu temu. Chasti 1 i 2. Consilium Medicum. 2014:Bolezni organov dykhaniya(Prilozhenie):4-9.
  9. Sandbo N. Mechanismis of fibrosis in IPF. in book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014:161-205. doi:10.1007/978-1-62703-682-5_8
  10. Beers MF, Morrisey EE. The three Rᴵs of lung health and disease: repair, remoduling, and regeneranion. J Clin Invest. 2011;121(6):2065-2073. doi:10.1172/JCI45961
  11. Tiery JP, Sleeman JP Cjmplex networks orhestrate epithelial-mesenchimal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142. doi:10.1038/nrm1835
  12. Cool CD, Groshong SD, Rai PR et al. Fibroblast foci are not discrete sites оf lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006;174 (6):654-658. doi:10.1164/rccm.200602-205OC
  13. Marinkovic A, Mih JD, Park JA et al. Improved throughput traction microscopy reveals pivotal role fore matrix stiffness in fibroblast cobtracyiluny and TGF-beta responsiveneaa. Am J Phisiol Lung Cell Mol Physiol. 2012;303(3):169-180. doi:10.1152/ajplung.00108.2012
  14. Raghu G, Collard HR, Egan JJ, and ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. doi:10.1164/rccm.2009-040GL
  15. Ryu JH, Moua T, Daniels CE, et al. Idiopathic pulmonary fibrosis:Evolving concepts. Mayo Clin Proc. 2014;89:1130-1142. doi:10.1016/j.mayocp.2014.03.016
  16. Tobin RW, PopeCE, Pellegrini CA et al. Increse prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804-1808. doi:10.1164/ajrccm.158.6.9804105
  17. Raghu G, Yang ST, Spada C at al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129:794-800. doi:10.1378/chest.129.3.794
  18. Lettieri CJ, Nathan SD, Barnett S at al. Chest. 2006;129:746-752. doi:10.1378/chest.129.3.746
  19. Lancaster LH, Mason WR, Parnell JA at al. Chest. 2009;136:772-778. doi:10.1378/chest.08-2776
  20. Brown AW, Shlobin OA, Weir N, at al. Dinamic patient counseling: A novel concept in idiopathic pulmonary fibrosis. Chest. 2012;142:1005-1010. doi:10.1378/chest.12-0298
  21. Selman M, Carillo G, Estrada A et al. Accelerated variantof idiopathic pulmonary fibrosis. PloS One. 2007;2:(57):e482. doi:10.1371/journal.pone.0000482
  22. Trujiillo G, Meneghin A, Flahertty KR et al. Sci Transl Med. 2010;2(57):ra82. doi:10.5214/ans.0972.7531.210407
  23. Collard HR, Moore BB,Flaherty KR et al. Acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-643. doi:10.1164/ajrccm.177.12.1398
  24. Lee JS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science: N York; 2014;349-358. doi:10.1007/978-1-62703-682-5_17
  25. Wadhwa A, Flaherty KR The keys to making a confident diagnosis of IPF. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;77-101. doi:10.1007/978-1-62703-682-5_5
  26. Wells AU, Ward S. Pulmanary Function tests in Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;103-121. doi:10.1007/978-1-62703-682-5_6
  27. Gibson GJ. Clinical tests of respiratory function London: Chappel and Hall; 1996:233-234. doi:10.1007/978-1-349-81333-9_9
  28. Welss AU, Desai SR, Rubens MB et al. Idiopathic Pulmonory Fibrosis: a cjmposite phisiologic index derived from disease extend observed on computer tomography. Am J Respir Crit Care Med. 2003;167:962-969. doi:10.1164/rccm.2111053
  29. Wells AU, Ward S. Pulmanary Function tests in Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;114. doi:10.1007/978-1-62703-682-5_6
  30. Hunninghake GW, Zimmerman MB, Schwartz DA et al. Utility of lung biopsy for diagnosis of Idiopathic Pulmonory Fibrosis. Am J Respir Crit Care Med. 2001;164 (2):193-196. doi:10.1164/ajrccm.164.2.2101090
  31. Utz JP, Ryu JH, Douglas WW et al. High short-term mortality following lung biopssy for usual interstitial pneumonia. Eur Resp J. 2001;17(2):175-179. doi:10.1183/09031936.01.17201750
  32. Lettieri Cj, Veerapan GR, Helman DL et al. Cest. 2005;127(5):1600-1605. doi:10.1378/chest.127.5.1600
  33. Canver CC, Mencer Jr RM. The role of open lung biopsy in early and late survival of ventilator-depends patients with diffuse idiopatic lung disease. J Cardiovassc Surg (Torino). 1994;35(2):151-155. doi:10.1016/S0031-3025(16)39212-1
  34. Athol U. Wells Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Resp Rev. 2013;22:128,158-162. doi:10.1183/09059180.00001213
  35. Richeldi L, Cjstabel U, Selman M et al. Efficacy of a tyrosine kinase ingibitor in Idiopathic Pulmonory Fibrosis. N Engl J Med. 2011;365:1079-1087. doi:10.1056/NEJMoa1103690
  36. Wollin L et al. Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis. J Pharmacol Exp Ther. 2014;349:209-220. doi:10.1124/jpet.113.208223
  37. Noble PW et al. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377:1760-1769. doi:10.1016/S0140-6736(11)60405-4
  38. King TE et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092. doi:10.1056/NEJMoa1402582
  39. Azuma A et al. Double- blind, placebo-controlled trial of pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047. doi:10.1517/13543784.14.11.1443
  40. Taniguchi H et al. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J. 2010;35:821-829. doi:10.1183/09031936.00005209
  41. Raghu G, Yang ST, Spada C et al. Outcomes of atypical symptoms attributed to gastroesophageal reflux. Chest. 2006;129(3):794-800. doi:10.1378/chest.129.3.794
  42. Holland AE, Swigris DO. The role of pulmonary Rehabilitation and supplemental oxygen therapy in the treatment of patients with Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;337-347. doi:10.1007/978-1-62703-682-5_16
  43. Lamas DJ, Lederer DJ. Lung transplantation for Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;363-377. doi:10.1007/978-1-62703-682-5_18
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.